Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

The needs of HCPs and patients are rapidly evolving. HCPs grapple with information overload and the increasing demand for personalised care, while patients seek convenient access to information ...

Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...

Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...

Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be self ...

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...

In this era of accelerating information, it is more critical than ever to be clear and engaging in medical publications – and that increasingly involves the skill of scientific storytelling, to ...

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category for ...

The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outweigh ...